BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report

Recent advancements in understanding the biology of glioblastomas (GBM) and increasing adoption of genomic sequencing in oncology practice have led to the discovery of several targetable mutations in these cancers. Among them, the BRAF V600E mutation can be found in approximately 3% of GBM. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Munjapara, Vasu, Heumann, Thatcher, Schreck, Karisa C., Gross, John M., Perez-Heydrich, Carlos, Gujar, Sachin K., Eberhart, Charles G., Holdhoff, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941771/
https://www.ncbi.nlm.nih.gov/pubmed/36825105
http://dx.doi.org/10.1159/000525660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941771/
https://www.ncbi.nlm.nih.gov/pubmed/36825105
http://dx.doi.org/10.1159/000525660

Ejemplares similares